Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Operating Margin: 2010-2025

Historic Operating Margin for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to 12.46%.

  • Niagen Bioscience's Operating Margin rose 620.00% to 12.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.48%, marking a year-over-year increase of 1499.00%. This contributed to the annual value of 7.76% for FY2024, which is 1446.00% up from last year.
  • Latest data reveals that Niagen Bioscience reported Operating Margin of 12.46% as of Q3 2025, which was up 21.77% from 10.24% recorded in Q2 2025.
  • Niagen Bioscience's 5-year Operating Margin high stood at 24.42% for Q4 2024, and its period low was -51.08% during Q3 2021.
  • In the last 3 years, Niagen Bioscience's Operating Margin had a median value of -0.79% in 2023 and averaged 3.44%.
  • As far as peak fluctuations go, Niagen Bioscience's Operating Margin slumped by 2,149bps in 2021, and later spiked by 3,607bps in 2023.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Operating Margin stood at -29.93% in 2021, then soared by 2,306bps to -6.88% in 2022, then spiked by 608bps to -0.79% in 2023, then soared by 2,521bps to 24.42% in 2024, then soared by 620bps to 12.46% in 2025.
  • Its Operating Margin was 12.46% in Q3 2025, compared to 10.24% in Q2 2025 and 15.66% in Q1 2025.